Incyte Corporation

This study gives continued access to the drug itacitinib for people who were already taking it in an earlier Incyte-sponsored trial and were doing well. It includes patients with myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. …

This study offers ongoing treatment with ruxolitinib (alone or with other cancer therapy) to people with pancreatic, colorectal, breast, or lung cancer who were already benefiting from it in a previous study. It includes only 10 participants who had stable disease and were tolera…

This study tests an experimental drug called INCB099280 in 73 people with advanced solid tumors who have not received prior immunotherapy. The goal is to see if the drug can shrink tumors and to check for side effects. Participants must have measurable disease and specific cancer…

This study tests whether adding two drugs (tafasitamab and lenalidomide) to standard rituximab therapy helps people with relapsed follicular or marginal zone lymphoma live longer without their cancer getting worse. About 654 adults who have already tried at least one prior treatm…

This study tests an experimental drug called INCB099280 in 63 adults with advanced squamous cell skin cancer that cannot be removed by surgery or radiation. The goal is to see if the drug can shrink tumors and to check for side effects. Participants take the drug by mouth and are…

This study tests a modified dosing schedule of the drug tafasitamab combined with lenalidomide in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have had 1 to 3 prior treatments and cannot undergo a stem-cell transplant. The main goal is to check saf…

This study tests whether adding axatilimab to the standard drug ruxolitinib works better for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. About 130 participants aged 12 and older will receiv…

This study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. Participants have had 1 to 3 previous therapies but cannot receive high-dose chemo or a stem cell trans…

This study tests whether adding two drugs, tafasitamab and lenalidomide, to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called DLBCL. About 900 patients with high-risk disease will take part. The goal is to see if the new combination keeps can…

This phase 3 study tests whether adding the drug INCMGA00012 to standard chemotherapy helps people with advanced non-small cell lung cancer live longer. About 583 participants with either squamous or nonsquamous lung cancer who have not had prior treatment will be enrolled. The s…

This early-stage study tests a new drug called INCB057643, given alone or with another drug (ruxolitinib), for people with myelofibrosis and other advanced blood cancers. The main goal is to check safety and side effects. About 140 adults whose cancer has not responded to prior t…

This early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not …

This study tests a drug called axatilimab against the best available treatments for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants must be 12 or older and have tried at least two prior treatments without success. T…

This study tests a new drug called povorcitinib for people with nonsegmental vitiligo, a condition that causes white patches on the skin. About 467 adults will take either the drug or a placebo daily for 52 weeks to see if it safely helps bring back skin color. Participants must …

This study tests a daily pill called povorcitinib to see if it can safely bring back skin color in people with nonsegmental vitiligo, a condition where white patches appear on the skin. About 450 adults will receive either the drug or a placebo for 52 weeks. The main goal is to m…

This study offers continued treatment with the drug parsaclisib (alone or with other drugs) to people with B-cell cancers who were already taking it in an earlier study and were benefiting. The main goal is to check safety and side effects. About 112 participants will take part.

This study tests a drug called retifanlimab, given alone or with other therapies, in people with advanced or metastatic endometrial cancer that worsened after platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow the disease. About 206 adults are taking …

This study tests an experimental drug called povorcitinib in 346 adults with prurigo nodularis, a condition causing intense itching and bumpy skin lesions. The goal is to see if the drug can significantly reduce itch and clear skin lesions compared to a placebo over 24 weeks. Par…

This study tests an experimental drug called povorcitinib for people with prurigo nodularis, a skin condition causing intense itching and hard bumps. About 349 adults aged 18 to 75 with at least 20 itchy lesions will receive either the drug or a placebo. The main goal is to see i…

This early-stage study tests a new drug called INCA033989 in 72 healthy adults aged 18 to 55. Participants receive a single dose either as an injection under the skin or through an IV. The goal is to measure how the drug moves through the body and check for any side effects. This…